BMC Cancer (Nov 2004)

SMAC is expressed <it>de novo </it>in a subset of cervical cancer tumors

  • Maldonado Vilma A,
  • De la Garza Jaime G,
  • Lopez Carlos M,
  • Cantu David,
  • Espinosa Magali,
  • Melendez-Zajgla Jorge

DOI
https://doi.org/10.1186/1471-2407-4-84
Journal volume & issue
Vol. 4, no. 1
p. 84

Abstract

Read online

Abstract Background Smac/Diablo is a recently identified protein that is released from mitochondria after apoptotic stimuli. It binds IAPs, allowing caspase activation and cell death. In view of its activity it might participate in carcinogenesis. In the present study, we analyzed Smac expression in a panel of cervical cancer patients. Methods We performed semi quantitative RT-PCR on 41 cervical tumor and 6 normal tissue samples. The study included 8 stage I cases; 16 stage II; 17 stage III; and a control group of 6 samples of normal cervical squamous epithelial tissue. Results Smac mRNA expression was below the detection limit in the normal cervical tissue samples. In contrast, 13 (31.7%) of the 41 cervical cancer biopsies showed detectable levels of this transcript. The samples expressing Smac were distributed equally among the stages (5 in stage I, 4 in stage II and 4 in stage III) with similar expression levels. We found no correlation between the presence of Smac mRNA and histology, menopause, WHO stage or disease status. Conclusions Smac is expressed de novo in a subset of cervical cancer patients, reflecting a possible heterogeneity in the pathways leading to cervical cancer. There was no correlation with any clinical variable.